|Articles|January 26, 2016

Bioclinica Provides RBM to Japan-Based CRO

EPS, a CRO based in Tokyo, Japan, has chosen Bioclinica’s COMPASS technology and professional services as its risk-based monitoring (RBM) solution for clinical trials in Japan. EPS President and Representative Director Hisashi Tanaka said in a release that the company wants to implement effective RBM services consistent with global regulatory authority initiatives. The COMPASS solution was chosen for many reasons, including a library of 44 standard KRIs and an ability to add additional custom KRIs; tracking and visualization at the study and site level, and robust alert and action recommendations.
 
 
Read the full release.
 
 

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.